Engagement with an AI- and CGM-Integrated Digital Health Platform Is Associated with Clinically Significant Weight Loss.

William Dixon¹, Stephanie Kim², Grace E Shryack¹, Dmitri Levonian¹, Dan Gusz¹, Sharam Fouladgar-Mercer¹, Jay S Skyler³

¹Signos, Palo Alto, California, USA.

²University of Washington, Seattle, Washington, USA.

³Diabetes Research Institute, University of Miami, Miami, Florida, USA.

PubMed DOI

Abstract

BACKGROUND: Obesity affects millions of U.S. adults and is linked to cardiometabolic disease. This study examined whether user engagement with the Signos app, which combines artificial intelligence (AI) and continuous glucose monitoring (CGM), is associated with weight loss. METHODS: This study included adults (≥18 years) with BMI ≥ 30 kg/m2 and without diabetes who enrolled in the Signos System,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.